The efficacy and safety of endostar combined gemcitabine and cisplatin in the treatment of non-small cell lung cancer: a meta-analysis

Abstract To determine the efficacy and safety of Endostar combined with gemcitabine and cisplatin in the treatment of NSCLC, and provide evidence-based reference for clinical drug use. Retrieved from Cochrane Library, PubMed, Embase, ClinicalTrials, CNKI, Wanfang and VIP database, randomized controlled trials (RCT) were collected. Pooled standard mean differences (SMD) and 95% confidence intervals (CI) were analyzed using R software with a random-effects model. Data from a total of 27 RCTs were included, involving 1646 patients were analyzed. Results of meta-analysis showed that response rate and clinical benefit rate of trial group were significantly higher than those of control group. There was no statistical significance in the incidence of leucopenia, thrombocytopenia and gastrointestinal reaction between 2 groups. The results showed that Endostar combined with gemcitabine and cisplatin may generally improve therapeutic efficacy of NSCLC patients, without increasing the incidence of adverse reactions.

摘要：为明确恩度（Endostar）联合吉西他滨（gemcitabine）与顺铂（cisplatin）治疗非小细胞肺癌（Non-Small Cell Lung Cancer, NSCLC）的疗效与安全性，为临床用药提供循证参考。本研究检索Cochrane图书馆、PubMed、Embase、ClinicalTrials、中国知网（CNKI）、万方数据及维普资讯数据库，收集随机对照试验（Randomized Controlled Trial, RCT）。采用R软件及随机效应模型，对合并标准化均数差（Standard Mean Difference, SMD）与95%置信区间（Confidence Interval, CI）进行分析。最终纳入共计27项随机对照试验，涉及1646例患者并开展分析。Meta分析结果显示，试验组的客观缓解率与临床获益率均显著高于对照组；两组患者的白细胞减少、血小板减少及胃肠道反应发生率均无统计学差异。研究结果表明，恩度联合吉西他滨与顺铂治疗非小细胞肺癌患者，可总体提升治疗疗效，且未增加不良反应的发生率。